A Multi-center, Single-arm, Phase II Clinical Study of Camrelizumab in Combination With Albumin Paclitaxel and Cisplatin for Neoadjuvant Treatment of Operable Locally Advanced Head and Neck Squamous Cell Carcinoma
Latest Information Update: 05 May 2023
At a glance
- Drugs Camrelizumab (Primary) ; Cisplatin (Primary) ; Paclitaxel (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 18 Jun 2021 New trial record